Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: A prospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1681-1687

  Alves, Marcelle D ^a   Ribeiro, Vanessa B ^a   Tessari, Jardel P ^b   Mattiello, Francine ^b   Bacco, Giordanna De ^b   Luz, Daniela I ^a   Vieira, Fabiane J ^b   Behle, Tainá F ^a   Pasqualotto, Alessandro C ^c   Zavascki, Alexandre P ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Antimicrobial therapy; Bacteraemia; Enterobacteriaceae; Pharmacokinetic pharmacodynamic

Indexed keywords

CEFEPIME; CREATININE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; SEPSIS; SEPTIC SHOCK; AGED; ANTIBIOTIC RESISTANCE; BACTEREMIA; DRUG EFFECTS; DRUG SUBSTITUTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; DRUG SUBSTITUTION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903881602     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku001     Document Type: Article

References (22)

1. Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6: 805-24.
2. Yahav D, Paul M, Fraser A et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 338-48.
3. Kim PW, Wu YT, Cooper C et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51: 381-9.
4. Nguyen TD, Williams B, Trang E. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009; 48: 902-4.
5. Leibovici L, Yahav D, Paul M. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51: 1350-1.
6. Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother 2011; 66: 1207-9.
7. Bhat SV, Peleg AY, Lodise TP Jr et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother 2007; 51: 4390-5.
8. Lee NY, Lee CC, Huang WH et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum β-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56: 488-95.
9. Roos JF, Bulitta J, Lipman J et al. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006; 58: 987-93.
10. Crandon JL, Bulik CC, Kuti JL et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-6.
11. Cheatham SC, Shea KM, Healy DP et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011; 37: 46-50.
12. Bauer KA, West JE, O'Brien JM et al. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57: 2907-12.
13. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
15. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
17. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections. J Infect 2007; 54: 463-8.
18. Lodise TP Jr, Rhoney DH, Tam VH et al. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis 2006; 54: 223-30.
19. Tam VH, McKinnon PS, Akins RL et al. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003; 47: 1853-61.
20. Ambrose PG, Owens RC Jr, Garvey MJ et al. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49: 445-53.
21. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22: 66-75.
22. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.